[The development of sulfonylurea late resistance].
D000367:Age Factors; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight; D002271:Carbutamide / Q000627:therapeutic use; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D003927:Diet, Diabetic; D004361:Drug Tolerance; D005260:Female; D005734:Gangrene / Q000209:etiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008134:Long-Term Care; D008297:Male; D013450:Sulfones / Q000009:adverse effects / Q000627:therapeutic use*; D013607:Tablets; D013997:Time Factors; D014044:Tolbutamide / Q000627:therapeutic use; D014508:Urea / Q000009:adverse effects / Q000627:therapeutic use*
D001786:Blood Glucose; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D013450:Sulfones; D013607:Tablets; D014508:Urea; D014044:Tolbutamide; D002271:Carbutamide
Zur Entwicklung der Sulfonylharnstoff-Spätresistenz.